Biochemical and Biophysical Research Communications 375 (2008) 619–622
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier.com/locate/ybbrc
Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab
Lei Zheng a,b,1, Bohua Li b,c,1, Weizhu Qian b,c, Lei Zhao b, Zhiguo Cao b, Shu Shi b, Jie Gao b, Dapeng Zhang b,c,
Sheng Hou b,c, Jianxin Dai b,c, Hao Wang b,c,*, Yajun Guo a,b,c,*
a
State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People’s Republic of China
International Joint Cancer Institute, The Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People’s Republic of China
c
National Engineering Research Center for Antibody Medicine, Shanghai 201203, People’s Republic of China
b
a r t i c l e
i n f o
Article history:
Received 11 August 2008
Available online 24 August 2008
Keywords:
IgE
Omalizumab
Monoclonal antibody
Epitope
Phage display peptide library
a b s t r a c t
Omalizumab is a humanized anti-IgE antibody that inhibits IgE binding to its receptors on mast cells
and basophils, thus blocking the IgE-mediated release of pharmacologic mediators from these cells.
Previous studies have indicated that omalizumab binds to the Ce3 domain of IgE, which is the binding
site of IgE receptors, but the precise epitope recognized by omalizumab is unknown. In this study, we
employed the phage display peptide library technology to select peptides binding to omalizumab. A
striking peptide sequence motif was recovered, which is homologous to the sequence 424HLP426 within
the Ce3 domain of IgE-Fc. Our results further indicated that omalizumab specifically bound to the
synthesized peptide ‘‘421THPHLPRALMRS432” containing the 424HLP426 motif in IgE-Fc. We therefore
conclude that the 424HLP426 motif is the omalizumab epitope. This epitope overlaps with the highaffinity IgE receptor-binding site, thus providing insights into the structural basis for the mechanism
of action of omalizumab.
Ó 2008 Elsevier Inc. All rights reserved.
Allergic diseases, such as asthma, allergic rhinitis and atopic
dermatitis, have become increasingly prevalent in the past few
decades. Most allergic diseases are caused by IgE-mediated hypersensitivity reactions [1,2]. IgE is one of the five classes of antibodies
in the human immune system, which accounts for a minute proportion of immunoglobulin in the blood. Allergic patients sensitized to an allergen produce increased amounts of IgE specific to
that allergen. These IgE molecules circulate in the blood and bind
to IgE receptors on the surface of basophils in the circulation and
mast cells in various tissues [3,4]. In an allergic reaction, the allergens enter the body and bind to the antigen-binding sites of IgE on
mast cells or basophils, crosslink the IgE molecules, aggregate the
underlying receptors, and thereby trigger the cells to release histamine and the other pharmacological mediators of the symptomatic
allergic response [2,4].
Mapping of the sites of the IgE-Fc that interact with IgE receptors is an important step toward the understanding and possible
manipulation of the allergic reaction. The crystal structure of the
human IgE-Fc bound to its high-affinity receptor (FceRI) a-chain
reveals that one receptor binds one dimeric IgE-Fc molecule asymmetrically through interactions at two sites, each involving one
* Corresponding authors. Fax: +86 21 25074349.
E-mail addresses: hwang_smmu@163.com (H. Wang), yjguo@smmu.edu.cn
(Y. Guo).
1
These authors contributed equally to this paper as first authors.
0006-291X/$ - see front matter Ó 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2008.08.055
Ce3 domain of the IgE-Fc [5]. The binding site for the low-affinity
IgE-Fc receptor (FceRII) in IgE-Fc is not precisely mapped, but also
lies in the Ce3 domains [6]. Omalizumab (Xolair) is a humanized
anti-IgE monoclonal antibody (mAb) approved for treatment of
moderate to severe asthma. Omalizumab tightly binds to free circulating IgE molecules and prevents binding of these molecules
to FceRI on mast cells and basophils and FceRII on various cell
types. It dose not bind to IgE already bound by either FceRI or FceRII. These binding characteristics allow omalizumab to inhibit allergen-induced responses without causing receptor crosslinking,
which could lead to anaphylaxis [7–9]. Previous studies have indicated that omalizumab also binds specifically to the Ce3 domain of
IgE, which is the binding site of FceRI and FceRII, thus eliminating
the ability of free IgE molecules to bind to both types of receptors
[8,10]. However, the precise epitope within the Ce3 domain of IgE
recognized by omalizumab has not yet been reported.
The phage display peptide library (PDPL) technology is a valuable tool for the exploration of epitopes recognized by antibodies.
Phage displaying a peptide that mimics the epitope of an antibody
can be selectively enriched by panning on antibody-coated plates
[11,12]. In this study, through panning a phage display peptide library with omalizumab, the specific epitope recognized by omalizumab was identified to be 424HLP426 within the Ce3 domain of
IgE-Fc. This epitope was observed to overlap with the FceRI-binding site, thereby revealing the structural basis for the mechanism
of action of omalizumab.
620
L. Zheng et al. / Biochemical and Biophysical Research Communications 375 (2008) 619–622
Fig. 1. Reactivity and deduced amino acid sequences of inserts of selected phage clones. Phage clones were isolated by panning the Ph.D.-7 PDPL with omalizumab. After
three rounds of panning, reactivity of positive phage clones with omalizumab was measured by ELISA as described in Materials and methods. Phage clones highly reactive in
ELISA were subjected to DNA sequence analysis. Deduced amino acid sequences of inserts from selected phage clones were aligned for the consensus motif, which is indicated
by underlined letters.
Materials and methods
Materials. The Ph.D.-7 Phage Display Peptide Library (PDPL) was
purchased from New England BioLabs (Beverly, MA). Omalizumab
and the anti-HER2 humanized antibody trastuzumab were respectively purchased from Genentech and Roche Ltd. Omalizumab and
trastuzumab were biotinylated using a biotin labeling kit (Roche,
Indianapolis, IN). Horseradish peroxidase (HRP)-conjugated avidin
was purchased from Jackson ImmunoResearch Laboratories (Avondale, PA). The human IgE-secreting cell line SKO-007 was obtained
from the American Type Culture Collection (ATCC). The IgE was
purified from the SKO-007 cell culture supernatant by affinity
chromatography on a sepharose 4B column conjugated with omalizumab. Peptides used in this study were synthesized by Yeli BioScientific Inc. (Shanghai, China). The quality of peptides was determined by analytical reverse-phase chromatography and mass
spectral analysis and the purity was greater than 95%.
Phage display library screening. The Ph.D.-7 PDPL is a filamentous
phage display system containing a repertoire of 1.2 109 sequences of random 7-amino acid peptides fused to the N-terminal
sequence of the M13 synthetic minor-coat protein PIII via the flexible linker GGGS. Biopanning of PDPLs with omalizumab was performed as described previously [12]. Briefly, the mAb omalizumab
was immobilized on 96-well plates. Then the wells were blocked
with 3% bovine serum albumin and incubated with phages
(1 1011 pfus) from the Ph.D.-7 PDPL at 4 °C for 1 h. The wells
were washed for five times and the phages that bound with omalizumab were amplified. Three rounds of selection were performed.
In the second and third round of selection, the library was precleared on trastuzumab.
ELISA screening of phage clones. 96-well plates were coated with
omalizumab (10 lg/well). After two washings and blockade of free
protein-binding sites, 100 ll of supernatant containing amplified
particles from each phage clone were added to wells and incubated
for 2 h at 37 °C. Following five washings, HRP-conjugated antiphage M13 monoclonal antibody (Amersham Biosciences) was
added and incubated for 1 h at 37 °C. After washing, 3,30 ,5,50 -tetramethylbenzidine (TMB) was added as a substrate and the absorbance was read at 450 nm using an immunoreader. Finally,
phage clones highly reactive in ELISA were subjected to DNA sequence analysis.
Western blot. For Western blot analysis, purified phage particles
(1 1010 pfus/lane) were electrophoresed on a 10% SDS–PAGE
under nonreducing conditions and then electrophoretically transferred onto polyvinylidine difluoride (PVDF) membranes (Amersham Biosciences). After blockade of its free protein-binding
sites, the PVDF membranes were treated with an appropriate dilution of omalizumab, followed by incubation with HRP-conjugated
goat anti-human IgG (Zymed, San Francisco, CA). Finally, the bands
were visualized by 3,30 -diaminobenzidine (DAB) (Sigma, St. Louis,
MO) as a peroxidase substrate.
Immunochemical assay. The reactivity of omalizumab with synthetic peptides was determined by ELISA assay. Briefly, 96-well
plates were coated with KLH-peptide. Following washing and
blockade of free protein-binding sites, different concentrations of
biotinylated omalizumab was added to each well and incubated
for 4 h, followed by the addition of an appropriate dilution of
HRP-conjugated avidin. After washing, TMB was added as a substrate and the absorbance was read at 450 nm using an
immunoreader.
The ability of synthetic peptides to block the interaction between the omalizumab and human IgE was also investigated.
Briefly, biotinylated omalizumab was incubated with different
concentrations of synthetic peptides for an hour. Then the mixture
Fig. 2. Western blot analysis of the specific reactivity of omalizumab with phage
minor-coat PIII protein-fused peptides from the selected phage clones. Purified
phage particles (1 1010 pfus/lane) isolated by biopanning omalizumab with the
Ph.D.-7 PDPL were electrophoresed on a 10% SDS–PAGE under nonreducing
conditions and then electrophoretically transferred onto PVDF membranes. After
blockade of its free protein-binding sites, the PVDF membranes were treated with
an appropriate dilution of omalizumab or trastuzumab, followed by incubation
with HRP-conjugated goat anti-human IgG. Finally, the bands were visualized by
DAB as a peroxidase substrate. A trastuzumab-specific phage clone (5A8) was used
as control. MW represents molecular weight.
L. Zheng et al. / Biochemical and Biophysical Research Communications 375 (2008) 619–622
621
Fig. 3. Reactivity of synthetic epitope peptides with omalizumab. (A) Ninety-six-well plates were coated with EP-KLH or 5A8-KLH. Following washing and blockade of free
protein-binding sites, different concentrations of biotinylated omalizumab was added to each well. After 4 h incubation, the antibody binding to peptide was detected by
sequential addition of an appropriate dilution of HRP-conjugated avidin. 5A8 is a trastuzumab-specific epitope peptide. 5A8 was coupled to KLH to generate 5A8-KLH. (B)
Competitive inhibition assay. Biotinylated omalizumab was incubated with different concentrations of synthetic peptides (EP or 5A8) for 1 h. Then the mixture was added to
96-well plates pre-coated with human IgE. After 2 h incubation, the wells were washed and the antibody binding to IgE was detected with an appropriate dilution of HRPconjugated avidin. 5A8 is a trastuzumab-specific epitope peptide. Results are expressed as percentage inhibition of binding compared with binding in the absence of inhibitor.
was added to 96-well plates pre-coated with human IgE and incubated for 2 h, followed by the addition of an appropriate dilution of
HRP-conjugated avidin. After washing, TMB was added as a substrate and the absorbance was read at 450 nm using an immunoreader. The percentage of inhibition was calculated using the
following formula: % inhibition = (A450in the absence of inhibitor
A450in the presence of inhibitor)/A450in the absence of inhibitor 100.
Results and discussion
Mapping of omalizumab-specific epitope on human IgE
Sequence analysis of omalizumab-positive phage clones identified five distinct sequences (Fig. 1). Alignment of the amino acid sequences of these clones resulted in the motif HLP and this could be
aligned with the sequence 424HLP426 located on the Ce3 domain of
human IgE (Fig. 1), suggesting that 424HLP426 was involved in the
binding of IgE-Fc to omalizumab. Moreover, His was present in
all phage-displayed peptides, suggesting that it might be crucial
for omalizumab-specific epitope expression.
Selection of phage-displayed peptides reactive with omalizumab
Reactivity of synthetic peptides with omalizumab
To identify the peptides recognized by omalizumab, phage
clones were isolated by panning the Ph.D.-7 PDPL with omalizumab. After the third round of panning, the binding of the cloned
phages to omalizumab was tested in an ELISA assay. The results
showed that 33 out of the 46 isolated phages specifically bound
to omalizumab (Fig. 1). The results of Western blot analysis also
indicated that omalizumab could bind to these 33 phage clones
(representative results are shown in Fig. 2). The reactivity was specific since omalizumab did not react with the trastuzumab-specific
phage clone 5A8, nor did omalizumab-specific phage clones react
with trastuzumab (Fig. 2). All omalizumab-positive phage clones
were selected for sequencing.
The peptide ‘‘421THPHLPRALMRS432” containing the 424HLP426
motif in human IgE-Fc was synthesized and denoted as EP. The ELISA assay results showed that omalizumab bound to KLH-conjugated EP peptide (EP-KLH) in a dose-dependent manner and the
binding was specific since omalizumab did not bind to control peptide-KLH (Fig. 3A) nor did EP-KLH react with trastuzumab (data not
shown). The capability of the EP peptide to block the binding of
omalizumab to human IgE was also determined. The results revealed that peptide EP effectively inhibited the binding of omalizumab to human IgE. In contrast, irrelevant control peptide did
not produce noteworthy inhibition on their interaction (Fig. 3B).
Fig. 4. Model of FceRIa-binding to IgE-Fc. The model was established using the software Discovery Studio 2.0 (Accelrys, San Diego, CA) based on the previously reported
crystal structure of FceRIa in complex with IgE-Fc [5]. IgE-Fc is shown in a surface representation and FceRIa is depicted in ball and stick form. (A) The IgE-Fc residues within
5 Å of FceRIa are defined as FceRIa-binding site residues and colored yellow. (B) The FceRIa-binding site residues that do not overlap with the omalizumab epitope residues
are colored yellow. The overlap of the omalizumab epitope and the FceRIa-binding site are shown in green. The omalizumab epitope residues that do not overlap with the
FceRIa-binding site residues are colored purple. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
622
L. Zheng et al. / Biochemical and Biophysical Research Communications 375 (2008) 619–622
These results further demonstrated that the
the omalizumab epitope.
451
HLP454 motif was
The epitope of omalizumab reveals the structural basis for its
mechanism of action
Human IgE-Fc has been crystalized in complex with its highaffinity receptor FceRIa. The crystal structure reveals that one
receptor molecule binds one dimeric IgE-Fc molecule asymmetrically through interactions at two sites (binding site 1 and binding
site 2), each involving one Ce3 domain of the IgE-Fc [5]. Therefore,
it is possible to compare the binding site of FceRI a-chain to IgE-Fc
with the localization of the omalizumab epitope identified in this
study. Fig. 4 illustrates the structure of FceRIa in complex with
IgE-Fc. The IgE-Fc residues within 5 Å of FceRIa are defined as
FceRIa-binding site residues and colored yellow (Fig. 4A). The omalizumab epitope identified here comprises the three amino acids
‘‘424HLP426” (Fig. 4B, green and purple), which include two of FceRIa-binding site residues 424HL425 in binding site 1 (Fig. 4B, green)
and three of FceRIa-binding site residues 424HLP426 in binding site
2 (Fig. 4B, green). Therefore, it can be concluded that the overlap of
the omalizumab-specific epitope and the FceRIa-binding site within the Ce3 domain of IgE-Fc is the structural basis for the inhibition
of IgE binding to FceRI by omalizumab. As a consequence of the
inhibition, the expression of FceRI on basophils, mast cells and
dendritic cells is also markedly downregulated [13–17]. Thus, IgE
effector functions are inhibited since the binding of IgE to FceRI
on IgE effector cells and the following activation of mast cells
and basophils are blocked. Moreover, omalizumab does not bind
to IgE already bound by FceRI, so it does not crosslink FceRI-bound
IgE and sensitize mast cells and basophils [10]. The overlap of the
omalizumab epitope and the FceRIa-binding site can also explain
why omalizumab is unable to bind to receptor-bound IgE.
In summary, the 451HLP454 motif within the Ce3 domain of IgEFc has been identified as the omalizumab epitope in the present
study. This epitope overlaps with the FceRI-binding site, thus providing insights into the structural basis for the mechanism of action of omalizumab.
Acknowledgments
This work was supported by grants from National Natural Science Foundation of China, Ministry of Science & Technology of China (973 and 863 Program Projects), and Shanghai Commission of
Science & Technology (key Laboratory and projects). The authors
thank Ms. Yang Yang and Ms. Jing Xu for their technical assistance.
References
[1] B. Lundbäck, Epidemiology of rhinitis and asthma, Clin. Exp. Allergy 28 (1998)
3–10.
[2] T.W. Chang, The pharmacological basis of anti-IgE therapy, Nat. Biotechnol. 18
(2000) 157–162.
[3] H. Metzger, G. Alcaraz, R. Hohman, J.P. Kinet, V. Pribluda, R. Quarto, The
receptor with high affinity for immunoglobulin E, Annu. Rev. Immunol. 4
(1986) 419–470.
[4] F.M. Davis, L.A. Gossett, K.L. Pinkston, R.S. Liou, L.K. Sun, Y.W. Kim, N.T. Chang,
T.W. Chang, K. Wagner, J. Bews, V. Brinkmann, H. Towbin, N. Subramanian, C.
Heusser, Can anti-IgE be used to treat allergy?, Springer Semin Immunopathol.
15 (1993) 51–73.
[5] S.C. Garman, B.A. Wurzburg, S.S. Tarchevskaya, J.P. Kinet, T.S. Jardetzky,
Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc
epsilonRI alpha, Nature 406 (2000) 259–266.
[6] H.J. Gould, B.J. Sutton, IgE in allergy and asthma today, Nat. Rev. Immunol. 8
(2008) 205–217.
[7] L.G. Presta, S.J. Lahr, R.L. Shields, J.P. Porter, C.M. Gorman, B.M. Fendly, P.M.
Jardieu, Humanization of an antibody directed against IgE, J. Immunol. 151
(1993) 2623–2632.
[8] G. D’Amato, A. Salzillo, A. Piccolo, M. D’Amato, G. Liccardi, A review of anti-IgE
monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgEmediated) asthma, Ther. Clin. Risk Manag. 3 (2007) 613–619.
[9] D. Nowak, Management of asthma with anti-immunoglobulin E: a review of
clinical trials of omalizumab, Respir. Med. 100 (2006) 1907–1917.
[10] C.E. Owen, Immunoglobulin E: role in asthma and allergic disease: lessons
from the clinic, Pharmacol. Ther. 113 (2007) 121–133.
[11] F. Perosa, E. Favoino, M.A. Caragnano, F. Dammacco, Generation of biologically
active linear and cyclic peptides has revealed a unique fine specificity of
rituximab and its possible cross-reactivity with acid sphingomyelinase-like
phosphodiesterase 3b precursor, Blood 107 (2006) 1070–1077.
[12] M. Binder, F.N. Vögtle, S. Michelfelder, F. Müller, G. Illerhaus, S. Sundararajan,
R. Mertelsmann, M. Trepel, Identification of their epitope reveals the structural
basis for the mechanism of action of the immunosuppressive antibodies
basiliximab and daclizumab, Cancer Res. 67 (2007) 3518–3523.
[13] L.A. Beck, G.V. Marcotte, D. MacGlashan, A. Togias, S. Saini, Omalizumabinduced reductions in mast cell Fc epsilon RI expression and function, J. Allergy
Clin. Immunol. 114 (2004) 527–530.
[14] H. Lin, K.M. Boesel, D.T. Griffith, C. Prussin, B. Foster, F.A. Romero, R. Townley,
T.B. Casale, Omalizumab rapidly decreases nasal allergic response and
FcepsilonRI on basophils, J. Allergy Clin. Immunol. 113 (2004) 297–302.
[15] S.S. Saini, D.W. MacGlashan Jr., S.A. Sterbinsky, A. Togias, D.C. Adelman, L.M.
Lichtenstein, B.S. Bochner, Down-regulation of human basophil IgE and FC
epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is
reversible in vitro and in vivo, J. Immunol. 162 (1999) 5624–5630.
[16] T. Feuchtinger, H. Bartz, A. von Berg, F. Riedinger, J. Brauburger, S. Stenglein, U.
Wahn, U. Schauer, Treatment with omalizumab normalizes the number of
myeloid dendritic cells during the grass pollen season, J. Allergy Clin.
Immunol. 111 (2003) 428–430.
[17] C. Prussin, D.T. Griffith, K.M. Boesel, H. Lin, B. Foster, T.B. Casale, Omalizumab
treatment downregulates dendritic cell FcepsilonRI expression, J. Allergy Clin.
Immunol. 112 (2003) 1147–1154.